KLK8

Kallikrein-8 · O60259 · KLK8 on Sugi Atlas →

1,133 patent compounds predicted against KLK8, 606 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL21585880	1.00	20/20
SCHEMBL21585884	1.00	20/20
SCHEMBL21585886	1.00	20/20
SCHEMBL21585889	1.00	20/20
SCHEMBL21590048	1.00	20/20
Hydrochloric Acid (SCHEMBL23753668)	1.00	20/20
Hydrochloric Acid (SCHEMBL23753671)	1.00	20/20
SCHEMBL29615860	1.00	20/20
Hydrochloric Acid (SCHEMBL29615866)	1.00	20/20
Hydrochloric Acid (SCHEMBL29615876)	1.00	20/20
SCHEMBL23753669	0.88	20/20
SCHEMBL23753670	0.88	20/20
SCHEMBL26332037	0.85	20/20
SCHEMBL21590051	0.84	20/20
SCHEMBL23760832	0.84	20/20
SCHEMBL29615859	0.84	20/20
SCHEMBL26332072	0.81	20/20
SCHEMBL23761029	0.75	20/20
SCHEMBL26332074	0.69	20/20
SCHEMBL29029650	0.59	20/20

Clinical trials — most relevant to KLK8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Research Study Looking at Mim8 in Children With Haemophilia A With or Without Inhibitors	PHASE3	COMPLETED
Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA	PHASE1/PHASE2	RECRUITING
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer	PHASE2	COMPLETED
Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer	PHASE2	COMPLETED
Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.	PHASE2	WITHDRAWN
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Study of SU11248 in Men With Advanced Prostate Cancer	PHASE2	COMPLETED
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy	PHASE2	RECRUITING
Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery	PHASE1/PHASE2	COMPLETED
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer	PHASE2	COMPLETED
An Open Label, Phase 1b, Ascending Dose Study of DM199	PHASE1	COMPLETED
Vaccination of Prostate Cancer Patients With MUC-2-KLH Conjugate Plus the Immunological Adjuvant QS21	PHASE1	COMPLETED
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer	PHASE1	COMPLETED
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.	PHASE1	COMPLETED
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)	PHASE1	COMPLETED
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents	PHASE1	SUSPENDED
Urinary Kallikrein and Hypertension: A Prospective Study	nan	COMPLETED
A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)	nan	ENROLLING_BY_INVITATION
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence	nan	COMPLETED
A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland	nan	UNKNOWN
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer	nan	COMPLETED
Predicting Prostate Biopsy Results With Biomarkers and mpMRI.	nan	COMPLETED
N/LP Ratio as Predictor of Mortality in Septic AKI Patients	nan	UNKNOWN
Minimally Invasive Kidney Transplantation	nan	UNKNOWN
APACA-Apheresis/acoustophoresis and Molecular Characterization of Prostate Cancer	nan	RECRUITING
Investigation of the Genetic Causes of Kallmann Syndrome and Reproductive Disorders	nan	COMPLETED
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Reteplase Intravenous Thrombolysis in the Treatment of Acute Ischemic Stroke	nan	NOT_YET_RECRUITING
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants	nan	COMPLETED
Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a KLK8 binder may also engage these)

Protein	Name	Similarity
Q61955	—	0.988	Q61955 →
O88780	—	0.986	O88780 →
P79204	—	0.980	P79204 →
P20718	—	0.979	P20718 →
P56435	—	0.975	P56435 →
KLK14	Kallikrein-14	0.975	landscape →
P21842	—	0.975	P21842 →
Q9QYN3	—	0.973	Q9QYN3 →
Q7JIG6	—	0.971	Q7JIG6 →
Q9UBX7	—	0.971	Q9UBX7 →
P52195	—	0.969	P52195 →
Q9H2R5	—	0.969	Q9H2R5 →
KLK7	Kallikrein-7	0.967	landscape →
CMA1	Chymase	0.966	landscape →
O46683	—	0.965	O46683 →
KLK2	Kallikrein-2	0.965	landscape →
Q61096	—	0.965	Q61096 →
GZMB	Granzyme B	0.964	landscape →
Q9XSM2	—	0.964	Q9XSM2 →
P33619	—	0.964	P33619 →
KLK6	Kallikrein-6	0.962	landscape →
KLK3	Prostate-specific antigen	0.962	landscape →
A7WPL7	—	0.962	A7WPL7 →
P19236	—	0.962	P19236 →
Q9Z0M1	—	0.962	Q9Z0M1 →
TPSD1	Tryptase delta (EC 3.4.21.59) (Delta-tryptase	0.961	landscape →
KLK5	Kallikrein-5	0.961	landscape →
Q28773	—	0.960	Q28773 →
KLK13	Kallikrein-13	0.960	landscape →
P15944	—	0.959	P15944 →